GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy

• DOI: 10.3389/fphar.2024.1396133
• Publication Date: 2024-05-17T04:36:00Z
• Authors: Chunyu Tian; Hongxu Zhang; Jianping Liu; Mengze Xu; Lihui Ma
• Keywords: Cardiotoxicity; GDF15; Neoadjuvant Therapy

Objective Growth differentiation factor 15 (GDF-15) is a stress-responsive cytokine that regulates myocardial injury, cardiac overloading pressure, and inflammation related to the risk of cardiovascular diseases events. The current study aimed investigate correlation GDF-15 levels with clinical features, biochemical indices, especially cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy. Methods A total 103 HER2-positive who underwent therapy (trastuzumab pertuzumab plus chemotherapy) were included. Serum before treatment detected by enzyme-linked immunosorbent assay. Cardiotoxicity was evaluated during referring decline ≥10 percentage points left ventricular ejection fraction from baseline an absolute level less than 50%. Results exhibited skewed distribution, median 714 (range: 207–1805) pg/mL. positively correlated age ( p = 0.037), diabetes 0.036), N-terminal pro-brain natriuretic peptide 0.013) cholesterol 0.086) troponin T 0.082), but these correlations not statistically significant. 6.8% experienced By comparison, greater those did 0.008). subsequent receiver operating characteristic curve revealed predicted risk, area under 0.803 (95% CI: 0.664–0.939). After multivariate adjustment, independently 0.020). Conclusion candidate biomarker for increased